1. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. (August 2018) Authors: Doria, A; Bass, D; Schwarting, A; Hammer, A; Gordon, D; Scheinberg, M; Fox, N L; Groark, J; Stohl, W; Kleoudis, C; Roth, D Journal: Lupus Issue: Volume 27:Number 9(2018) Page Start: 1489 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0231 Safety of subcutaneous belimumab in patients with systemic lupus erythematosus: a 6-month open-label extension study. (15th June 2017) Authors: Doria, A; Stohl, W; Schwarting, A; Scheinberg, M; Hammer, A; Kleoudis, C; Groark, J; Fox, NL; Roth, D; Bass, D; Gordon, D Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 861 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0240 Phase 3 trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE). (15th June 2017) Authors: Merrill, J; Martin, RS; Shanahan, WR; Scheinberg, M; Kalunian, K; Wofsy, D Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 864 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗